ArticlePathogens (Basel, Switzerland)2025
An Update of Epidemiological Trends in Enzootic Bovine Leukosis in Italy and an Analysis of Risk Factors Associated with Infection Persistence.
Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2017, the Commission Implementing Decision (European Union [EU]) 2017/1910 officially declared Italy to be enzootic bovine leukosis (EBL)-free. The Commission Delegated Regulation (EU) 2020/689 laid criteria to maintain an official disease-free status. While some infection clusters persist in restricted areas, specific measures are being implemented to eliminate pockets of viral persistence. This updated analysis of current data, concerning epidemiological trends of EBL in Italy from January 2022 to December 2024, aimed to analyze the status of infection clusters in terms of risk factors associated with bovine leukemia virus (BLV) seropositivity to evaluate the effectiveness of the eradication measures. Our findings highlighted an improvement in EBL eradication; however, the Latium region lags behind in terms of disease eradication while the situation in Apulia is being resolved. Campania, which has implemented restrictive and consistent health measures, has the lowest prevalence and incidence rates compared with previous years. Identifying and assessing risk factors that favor EBL persistence in infection clusters is essential as is implementing specific measures to eliminate such clusters, thereby enabling disease eradication and the adoption of targeted prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.